Literature DB >> 23720194

Longitudinal features of STIR bright signal in FSHD.

Seth D Friedman, Sandra L Poliachik, Randolph K Otto, Gregory T Carter, Christopher B Budech, Thomas D Bird, Daniel G Miller, Dennis W W Shaw.   

Abstract

INTRODUCTION: Magnetic resonance imaging of muscle shows short tau-inversion recovery (STIR) brightness in autosomal dominant facioscapulohumeral muscular dystrophy (FSHD1) suggestive of active inflammation/injury. We measured the longitudinal stability/progression of this potential disease biomarker.
METHODS: Nine subjects underwent calf MRI imaging over 2 years. Two radiologists evaluated qualitative muscle changes.
RESULTS: In 3/9 subjects, calf muscles demonstrated moderate/severe STIR hyperintensity at Time 1 that had progressed to fatty replacement 2 years later (Time 2). In the remaining subjects, moderate/severe muscle STIR abnormalities, when present, were consistent between exams. Mild STIR+ elevations had roughly similar patterns between exams.
CONCLUSIONS: Moderate/severe STIR hyperintensities often foreshadow fatty replacement over a 2-year interval. Whether longer time courses are required to observe muscle degeneration and fatty replacement in some subjects remains to be explored.

Entities:  

Mesh:

Year:  2014        PMID: 23720194     DOI: 10.1002/mus.23911

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  21 in total

1.  DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle.

Authors:  Zizhen Yao; Lauren Snider; Judit Balog; Richard J L F Lemmers; Silvère M Van Der Maarel; Rabi Tawil; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2014-05-26       Impact factor: 6.150

2.  MRI as outcome measure in facioscapulohumeral muscular dystrophy: 1-year follow-up of 45 patients.

Authors:  Grete Andersen; Julia R Dahlqvist; Christoffer R Vissing; Karen Heje; Carsten Thomsen; John Vissing
Journal:  J Neurol       Date:  2016-12-20       Impact factor: 4.849

Review 3.  Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical Trials.

Authors:  Pierre G Carlier; Benjamin Marty; Olivier Scheidegger; Paulo Loureiro de Sousa; Pierre-Yves Baudin; Eduard Snezhko; Dmitry Vlodavets
Journal:  J Neuromuscul Dis       Date:  2016-03-03

Review 4.  Advancements in magnetic resonance imaging-based biomarkers for muscular dystrophy.

Authors:  Doris G Leung
Journal:  Muscle Nerve       Date:  2019-05-14       Impact factor: 3.217

5.  Magnetic resonance imaging in facioscapulohumeral muscular dystrophy.

Authors:  Doris G Leung
Journal:  Muscle Nerve       Date:  2018-01-23       Impact factor: 3.217

6.  Clinical Muscle Testing Compared with Whole-Body Magnetic Resonance Imaging in Facio-scapulo-humeral Muscular Dystrophy.

Authors:  J U Regula; L Jestaedt; F Jende; A Bartsch; H-M Meinck; M-A Weber
Journal:  Clin Neuroradiol       Date:  2015-04-10       Impact factor: 3.649

7.  Relationship between markers of disease activity and progression in skeletal muscle of GNE myopathy patients using quantitative nuclear magnetic resonance imaging and 31P nuclear magnetic resonance spectroscopy.

Authors:  Harmen Reyngoudt; Benjamin Marty; Ericky Caldas de Almeida Araújo; Pierre-Yves Baudin; Julien Le Louër; Jean-Marc Boisserie; Anthony Béhin; Laurent Servais; Teresa Gidaro; Pierre G Carlier
Journal:  Quant Imaging Med Surg       Date:  2020-07

Review 8.  Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle.

Authors:  Amy E Campbell; Andrea E Belleville; Rebecca Resnick; Sean C Shadle; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2018-08-01       Impact factor: 6.150

9.  Whole-body magnetic resonance imaging evaluation of facioscapulohumeral muscular dystrophy.

Authors:  Doris G Leung; John A Carrino; Kathryn R Wagner; Michael A Jacobs
Journal:  Muscle Nerve       Date:  2015-03-31       Impact factor: 3.852

10.  Muscle Quantitative MR Imaging and Clustering Analysis in Patients with Facioscapulohumeral Muscular Dystrophy Type 1.

Authors:  Emilie Lareau-Trudel; Arnaud Le Troter; Badih Ghattas; Jean Pouget; Shahram Attarian; David Bendahan; Emmanuelle Salort-Campana
Journal:  PLoS One       Date:  2015-07-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.